Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 7.510
Filtrar
1.
Asian Pac J Cancer Prev ; 24(1): 87-92, 2023 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-36708556

RESUMO

BACKGROUND: Angiosarcoma (AS) of the urinary bladder is a very rare and aggressive malignancy with a dismal outcome. CASE REPORT: Here, we report a primary epithelioid angiosarcoma (EAS) of the urinary bladder in a forty-nine-year-old male patient who presented with severe hematuria. Cystoscopic examination revealed hemorrhagic ulcerated bladder mucosa but no definite mass lesions. Intractable hematuria raised the initial clinical impression of idiopathic hemorrhagic cystitis. Analysis of the cystoscopic biopsy revealed features of old bilharzial cystitis, markedly atypical epithelioid endothelial cells arranged as primitive anastomosing vascular structures and expressing vascular markers. The diagnosis of EAS was established. The patient developed intractable severe hematuria, and a radical cystoprostatectomy was performed. The patient was started on chemotherapy but suddenly developed widespread distant metastasis (liver, lung, suprarenal glands, and lymph nodes) and succumbed to death two months after the surgery. CONCLUSION: To the best of these authors' knowledge, we presented the first report of primary EAS arising in a bilharzial bladder. The relevant studies were discussed.


Assuntos
Cistite , Hemangiossarcoma , Masculino , Humanos , Pessoa de Meia-Idade , Hemangiossarcoma/cirurgia , Hemangiossarcoma/diagnóstico , Hemangiossarcoma/patologia , Bexiga Urinária/cirurgia , Bexiga Urinária/patologia , Hematúria/etiologia , Células Endoteliais
2.
Zhonghua Zhong Liu Za Zhi ; 45(1): 74-81, 2023 Jan 23.
Artigo em Chinês | MEDLINE | ID: mdl-36709123

RESUMO

Objective: To evaluate the efficacy and safety of different medical treatment in advanced or unresectable angiosarcoma. Methods: This study was a single-center retrospective clinical study. Fifty-five advanced or unresectable angiosarcoma patients treated in Sun-Yat Sen University Cancer Center from January 2005 to August 2020 were enrolled. There were 34 patients who received first-line doxorubicin-based chemotherapy (doxorubicin group), 12 patients received first-line doxorubicin or liposome doxorubicin plus paclitaxel or albumin bound paclitaxel chemotherapy (combination therapy group), and 4 patients received first-line paclitaxel-based treatment (paclitaxel group). There were 6 patients who received anti-angiogenesis targeted therapy, another 2 patients received anti-PD-1 antibody plus anti-angiogenesis targeted therapy. Targeted therapy and immunotherapy plus targeted therapy included 5 cases of first-line therapy and 3 cases of second-line therapy. The therapeutic effect was evaluated by RECIST 1.1 standard. The adverse reactions were evaluated by CTCAE4.0 standard. Kaplan-Meier survival analysis was evaluated with Log rank test. Cox proportional hazard model was used to analyze the influencing factors. Results: There were 18 patients achieved partial response (PR) in 34 patients in the doxorubicin group, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 15 months. Four patients achieved PR in 12 patients in the combination therapy group, mPFS and mOS were 4 months and 19 months. Two patients achieved PR in 4 patients in the paclitaxel group, mPFS and mOS were 3 months and 9 months. However, only 1 in 6 patients achieved PR for anti-angiogenesis targeted therapy, mPFS and mOS were 3 months and 16 months. Two patients who received anti-PD-1 immunotherapy combined with anti-angiogenesis targeted therapy acquired PR for 17 months and more than 16 months. Median PFS (7.5 months) were longer in those with primary liver, lung and spleen angiosarcoma than in those with other primary site (3.0 months, P=0.028). The mOS (20 months) was longer in females than that in males (12 months, P=0.045). Primary tumor site, sex, age and treatment were not independent prognostic factors for angiosarcoma patients (P>0.05). Grade 3-4 cardiac toxicity was found in 2 patients in the combination therapy group. Conclusions: Doxorubicin-based and paclitaxel-based chemotherapy are the most important treatment for advanced angiosarcoma. Potential efficacy for targeted therapy combined with anti-PD-1 immunotherapy are showed in some patients with long duration of response and moderate adverse event.


Assuntos
Hemangiossarcoma , Masculino , Feminino , Humanos , Estudos Retrospectivos , Paclitaxel/efeitos adversos , Doxorrubicina/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
3.
J Cardiothorac Surg ; 18(1): 35, 2023 Jan 18.
Artigo em Inglês | MEDLINE | ID: mdl-36653856

RESUMO

Poland's syndrome, a rare genetic disorder that accompanies malignancies, musculoskeletal disorders, cardiac and genitourinary syndromes. There is no study that represents the association between cardiac angiosarcoma and Poland's syndrome. A 24-year-old female patient previously diagnosed with Poland's syndrome was admitted to our hospital complaining of dyspnea. Diagnostic imaging showed an irregular mass in the right atrial cavity. After successful surgery, she was discharged uneventfully and the 3rd month oncologic follow-up reveals none of residual mass. The coexistence has not been diagnosed and treated in a cardiac surgery department before. With this presentation, we aimed to contribute to the literature with this presentation, for the right and early diagnosis and management of possible new cases in the future can be diagnosed and treated correctly and early.


Assuntos
Neoplasias Cardíacas , Hemangiossarcoma , Neoplasias do Mediastino , Síndrome de Poland , Neoplasias do Timo , Feminino , Humanos , Adulto Jovem , Adulto , Hemangiossarcoma/complicações , Hemangiossarcoma/diagnóstico , Hemangiossarcoma/cirurgia , Neoplasias do Mediastino/complicações , Neoplasias do Timo/complicações , Síndrome de Poland/complicações , Síndrome de Poland/diagnóstico , Síndrome de Poland/cirurgia , Neoplasias Cardíacas/complicações , Neoplasias Cardíacas/diagnóstico , Neoplasias Cardíacas/cirurgia
4.
World J Gastroenterol ; 29(3): 561-578, 2023 Jan 21.
Artigo em Inglês | MEDLINE | ID: mdl-36688020

RESUMO

BACKGROUND: Angiosarcoma is a highly malignant soft-tissue sarcoma derived from vascular endothelial cells that mainly occurs in the skin and subcutaneous tissues. Small-intestinal angiosarcomas are rare, and the prognosis is poor. CASE SUMMARY: We reported a case of primary multifocal ileal angiosarcoma and analyze previously reported cases to improve our understanding of small intestinal angiosarcoma. Small intestinal angiosarcoma is more common in elderly and male patients. Gastrointestinal bleeding, anemia, abdominal pain, weakness, and weight loss were the common symptoms. CD31, CD34, factor VIII-related antigen, ETS-related gene, friend leukemia integration 1, and von Willebrand factor are valuable immunohistochemical markers for the diagnosis of small-intestinal angiosarcoma. Small-intestinal angiosarcoma most commonly occurs in the jejunum, followed by the ileum and duodenum. Radiation and toxicant exposure are risk factors for angiosarcoma. After a definite diagnosis, the mean and median survival time was 8 mo and 3 mo, respectively. Kaplan-Meier survival analysis showed that age, infiltration depth, chemotherapy, and the number of small intestinal segments invaded by tumor lesions were prognostic factors for small intestinal angiosarcoma. Multivariate Cox regression analysis showed that chemotherapy and surgery significantly improved patient prognosis. CONCLUSION: Angiosarcoma should be considered for unexplained melena and abdominal pain, especially in older men and patients with a history of radiation exposure. Prompt treatment, including surgery and adjuvant chemotherapy, is essential to prolonging patient survival.


Assuntos
Hemangiossarcoma , Neoplasias do Jejuno , Humanos , Masculino , Idoso , Hemangiossarcoma/diagnóstico , Hemangiossarcoma/terapia , Hemangiossarcoma/patologia , Células Endoteliais/patologia , Intestino Delgado/patologia , Neoplasias do Jejuno/diagnóstico , Neoplasias do Jejuno/terapia , Neoplasias do Jejuno/patologia , Prognóstico , Fator de von Willebrand
6.
Arkh Patol ; 84(6): 52-55, 2022.
Artigo em Russo | MEDLINE | ID: mdl-36469718

RESUMO

The article presents a rare case of bone marrow metastasis of the spleen angiosarcoma. The observation is of particular interest due to the fact that secondary bone marrow damage in angiosarcoma in the vast majority of cases is due by primary tumor growth in the spleen. Clinically, such cases may resemble the course of blood diseases with hematological disorders and splenomegaly. Patients come into the field of view of a hematologist, and the final diagnosis is unexpected to the attending physician. Detection of angiosarcoma growth in a bone marrow trephine biopsy during morphological examination can be a rare finding for a pathologist. In this regard, the presented case is of interest not only for pathologists, but also for doctors of clinical specialties.


Assuntos
Neoplasias da Medula Óssea , Hemangiossarcoma , Neoplasias Esplênicas , Humanos , Hemangiossarcoma/diagnóstico , Hemangiossarcoma/complicações , Hemangiossarcoma/patologia , Medula Óssea/patologia , Neoplasias Esplênicas/diagnóstico , Neoplasias Esplênicas/complicações , Neoplasias Esplênicas/patologia
7.
Anticancer Res ; 42(12): 5991-5997, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36456135

RESUMO

BACKGROUND/AIM: Radiotherapy for angiosarcoma of the scalp has not been standardised yet. Hence, we aimed to retrospectively analyse the outcomes of patients treated with electron beam therapy or intensity-modulated radiation therapy (IMRT) for unresectable angiosarcoma of the scalp. PATIENTS AND METHODS: Data from patients treated with chemoradiotherapy or radiotherapy alone for unresectable angiosarcoma of the scalp between March 2009 and March 2021 were evaluated. Survival and local control rates were analysed using the Kaplan-Meier method, and the log-rank test was used to compare groups. Adverse events were analysed using the Common Terminology Criteria for Adverse Events ver. 5.0. RESULTS: Sixteen patients were eligible for the study. Eight patients were treated with electron beam therapy and eight patients with IMRT. The median follow-up period was 18.0 months. The median radiation dose was 57 Gy in 19 fractions in the electron beam therapy group and 70 Gy in 35 fractions in the IMRT group. In the IMRT group, acute non-haematologic toxicity was observed in two patients with grade 3 dermatitis. The one-year overall survival rate, progression-free survival rate, and local control rate in the electron beam therapy group were 80.8%, 56.3%, and 77.4%, respectively, and the corresponding values in the IMRT group were 100%, 75%, and 100%, respectively. One-year local control was significantly better in the IMRT group compared to that in the electron beam therapy group (p=0.016). CONCLUSION: IMRT for angiosarcoma of the scalp may improve local control rates compared to electron beam therapy, but long-term follow-up studies are required to validate this finding.


Assuntos
Hemangiossarcoma , Radioterapia de Intensidade Modulada , Humanos , Hemangiossarcoma/radioterapia , Couro Cabeludo , Radioterapia de Intensidade Modulada/efeitos adversos , Elétrons , Estudos Retrospectivos
8.
Int J Mol Sci ; 23(24)2022 Dec 16.
Artigo em Inglês | MEDLINE | ID: mdl-36555675

RESUMO

Primary breast angiosarcoma, with de novo appearance and not associated with exposure to radiation or lymphedema, is a rare pathology representing less than 0.05% of the neoplasms related to this organ. The pathology is characterized by its aggressiveness, poor prognosis, and difficulties in its differential diagnosis. This article reports the case of a 55-year-old white woman with no family history of cancer, with a rapidly growing mass in the left mammary gland that ulcerates and bleeds. It is confirmed as primary breast angiosarcoma by immunostaining in the tumor tissue for CD31, CD34, and FLI-1. In addition, a sample of neoplastic and healthy tissues is collected from the patient for RNA sequencing; the results are contrasted with a tissue sample from a patient with Luminal A subtype of breast cancer, as well as data from other cases of angiosarcoma available in public databases. These findings revealed a genetic profile associated with the immune and inflammatory response in the patient's sample when compared to available angiosarcoma data; these molecular patterns are consistent with other recent studies. Due to the rarity of the disease, the studies carried out on each patient contribute to the expanding knowledge of the etiology and molecular pathways that are still partially known and continue to be the subject of research. Aside from a comparative transcriptome study, this article aims to provide an update on the state of knowledge about this disease.


Assuntos
Neoplasias da Mama , Hemangiossarcoma , Feminino , Humanos , Pessoa de Meia-Idade , Hemangiossarcoma/diagnóstico , Transcriptoma , Neoplasias da Mama/patologia , Perfilação da Expressão Gênica
10.
PLoS One ; 17(12): e0279594, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36548371

RESUMO

Canine splenic hemangiosarcoma (HSA) is an aggressive tumor with a short overall survival time (OST) despite treatment with splenectomy and adjuvant doxorubicin. Modulation of the immune system has been shown to be effective for a variety of human tumors, and may be effective for canine tumors, including HSA. Immunocidin® is a non-specific immunotherapy based on a mycobacterial cell wall fraction. Preliminary work suggests Immunocidin® is safe to give intravenously (IV) in tumor-bearing dogs. This work aimed to evaluate the safety of doxorubicin and Immunocidin® combination in dogs with naturally occurring splenic HSA. A secondary aim of this study was to collect preliminary efficacy data to support a subsequent comprehensive, prospective clinical trial in canine patients with HSA, if the combination of doxorubicin and Immunocidin® was found to be safe. Eighteen dogs with stage II-III splenic HSA were recruited to receive 5 doses of sequential IV doxorubicin and Immunocidin® at two-week intervals following splenectomy. Adverse events (AEs) were graded according to the Veterinary Cooperative Oncology Group v1.1 (VCOG) scheme. Overall survival time was calculated from the date of splenectomy to date of death or loss to follow-up. AEs during administration were infrequent, the most common being hypertension. One patient developed limb and facial twitching and was removed from the study. After infusion, common AEs included lethargy, hyporexia, and diarrhea. One patient developed VCOG grade 5 diarrhea, thrombocytopenia, and anemia. Modifications in the treatment regimen were made to prevent these signs in subsequent patients. The median OST in dogs treated with the combination therapy was estimated at 147 days (range: 39-668 days). Although generally safe, the combination of doxorubicin and Immunocidin® appeared to cause more gastrointestinal effects than doxorubicin alone, and no apparent improvement in OST was noted in this population of dogs.


Assuntos
Doenças do Cão , Hemangiossarcoma , Neoplasias Esplênicas , Animais , Cães , Humanos , Doenças do Cão/tratamento farmacológico , Doxorrubicina/efeitos adversos , Hemangiossarcoma/tratamento farmacológico , Hemangiossarcoma/veterinária , Imunoterapia , Estudos Prospectivos , Neoplasias Esplênicas/veterinária
11.
Rev. esp. enferm. dig ; 114(12): 753-754, diciembre 2022. ilus
Artigo em Espanhol | IBECS | ID: ibc-213539

RESUMO

Varón de 54 años que consulta por lumbalgia de 5 semanas de evolución refractaria a analgésicos habituales y pérdida de peso significativa. El PET-TAC evidenció una masa retroperitoneal en contacto con la pared anterior de la aorta abdominal. Tras comentarlo con la Unidad de Endoscopias, se decide realizar ecoendosocopia y PAAF por la accesibilidad y el carácter menos invasivo con resultado anatomopatológico de angiosarcoma de aorta. (AU)


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Hemangiossarcoma , Aorta , Endossonografia , Dor Lombar
12.
Rev. esp. enferm. dig ; 114(12): 761-762, diciembre 2022. ilus
Artigo em Espanhol | IBECS | ID: ibc-213547

RESUMO

El angiosarcoma esplénico es una neoplasia muy infrecuente y agresiva proveniente del endotelio vascular esplénico cuyo pronóstico es funesto a pesar del tratamiento quirúrgico. Su diagnóstico preoperatorio mediante pruebas de imagen supone un desafío por su similitud con otros tumores esplénicos vasculares. El tratamiento es la esplenectomía aunque rara vez es curativo dada la naturaleza agresiva y metastásica de la enfermedad. (AU)


Assuntos
Humanos , Hemangiossarcoma , Esplenectomia , Astenia , Dor Abdominal , Ultrassonografia
13.
Medicine (Baltimore) ; 101(45): e31755, 2022 Nov 11.
Artigo em Inglês | MEDLINE | ID: mdl-36397415

RESUMO

RATIONALE: Septic pulmonary embolism (SPE) and subsequent pneumothorax are rare but serious conditions. We report a case of SPE and pneumothorax caused by central venous port (CV port) infection. PATIENT CONCERNS: A 73-year-old woman, who underwent chemoradiotherapy for a head angiosarcoma and a CV port placement, presented with general malaise and myalgia. DIAGNOSIS: A laboratory examination showed high levels of inflammatory markers. Chest computed tomography showed fluid collection around the CV port and multiple ground-glass opacities and nodular shadows in the bilateral lung field. She was admitted with a diagnosis of SPE due to CV port infection. The port was removed, and antibiotic administration was initiated; however, she was intubated because of refractory septic shock. Methicillin-susceptible Staphylococcus aureus was detected in the blood and pus around the port site. INTERVENTIONS: Her respiratory status did not improve despite recovering from septic shock, and radiologic findings showed a left pneumothorax and exacerbation of SPE on day 9. Her condition was judged ineligible for surgery for pneumothorax, and chest tube thoracostomy was continued. OUTCOMES: Air leaks persisted after chest tube thoracostomy, and her respiratory status did not improve despite ventilator management and recruitment maneuvers. Moreover, a right pneumothorax developed on day 19. Her respiratory status gradually worsened, and she died on day 21. Autopsy showed multiple cavitary lesions in the bilateral lungs and emboli containing organization and inflammatory cells that obstructed the pulmonary arterioles. LESSONS: This case indicates that CV port-related infections are infrequent and difficult to diagnose; understanding the clinical features of SPE is important because of its high mortality rate; and pneumothorax secondary to SPE is a rare but serious condition and is difficult to treat during ventilator management.


Assuntos
Hemangiossarcoma , Pneumotórax , Embolia Pulmonar , Sepse , Choque Séptico , Lesões do Sistema Vascular , Humanos , Feminino , Idoso , Hemangiossarcoma/patologia , Pneumotórax/terapia , Pneumotórax/complicações , Autopsia , Choque Séptico/terapia , Choque Séptico/complicações , Sepse/complicações , Lesões do Sistema Vascular/complicações , Quimiorradioterapia/efeitos adversos , Embolia Pulmonar/terapia , Embolia Pulmonar/complicações
14.
J Cardiothorac Surg ; 17(1): 288, 2022 Nov 16.
Artigo em Inglês | MEDLINE | ID: mdl-36384630

RESUMO

BACKGROUND: Angiosarcomas are the most common malignant tumors of the heart and great vessels. Late onset and unspecific symptoms are reasons why a diagnosis is made rather late at a time when most tumors have already metastasized. We report a rare case of an angiosarcoma presenting as pulmonary artery emboli. CASE PRESENTATION: A 66-year-old patient was initially admitted to the hospital with a STEMI. Days later a successful reanimation due to ventricular fibrillation followed. An emboli of the pulmonary artery was diagnosed as the cause and after a lysis therapy the patient was discharged. A few weeks later the patient suffered an episode of absolute arrhythmia. TTE as well as CT-Scan showed an emboli of the pulmonary artery and a pericardial effusion with compression to the right ventricle. Intraoperative findings, showed an infiltrating tumor of the pulmonary artery, the pulmonary valve, the RVOT, the LA and LV. A resection of the tumor from the pulmonary artery, valve and RVOT was carried out. A new pulmonary valve was implanted with the reconstruction of the RVOT and pulmonary artery. Due to LV infiltration, only a palliative surgical approach was possible. Despite an uncomplicated postoperative course, the patient died at home two months later. CONCLUSION: Although a rarity, a tumor of the pulmonary artery should be taken into consideration as a differential diagnosis to pulmonary artery emboli. Development of better diagnostic tools (specific tumor markers) and more effective chemotherapeutic agents is necessary to improve the prognosis of these patients.


Assuntos
Hemangiossarcoma , Neoplasias Pulmonares , Embolia Pulmonar , Valva Pulmonar , Humanos , Idoso , Artéria Pulmonar/diagnóstico por imagem , Artéria Pulmonar/cirurgia , Hemangiossarcoma/complicações , Hemangiossarcoma/diagnóstico , Hemangiossarcoma/cirurgia , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/cirurgia
15.
Am J Dermatopathol ; 44(12): 955-957, 2022 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-36395451

RESUMO

ABSTRACT: Cutaneous angiosarcomas (AS) are uncommon and morphologically heterogeneous. Recently, a distinctive lymphatic-type AS with prominent lymphocytic infiltrate has been observed. Although conventional AS typically bear poor prognosis, lymphatic-type AS with prominent lymphocytic infiltrate and pseudolymphomatous AS show prolonged survival with rare extracutaneous spread. We describe a unique case of AS in a 55-year-old woman who received surgical resection and radiation therapy for her prior myxoid liposarcoma. She developed a suspected recurrence 15 years later. Microscopically, the lesion showed an infiltration of the reticular dermis by irregular interanastamosing vascular spaces lined by atypical endothelial cells with nuclear "hobnailing" and hyperchromasia. A prominent intratumoral and peritumoral lymphocytic infiltrate obscuring the tumor cells was also present. The tumor cells were diffusely positive for endothelial cell markers, including D2-40. Notably, there was no evidence of MYC gene amplification by FISH. Additional NGS-based molecular analysis demonstrated no significant genetic mutations. The patient is alive with a history of two local recurrences, but no evidence of metastasis. We present this case to raise awareness of MYC-nonamplified secondary lymphatic-type AS with prominent lymphocytic infiltrate (pseudolymphomatous AS) and to discuss its differential diagnosis.


Assuntos
Hemangiossarcoma , Lipossarcoma Mixoide , Vasos Linfáticos , Pseudolinfoma , Neoplasias Cutâneas , Feminino , Humanos , Adulto , Hemangiossarcoma/genética , Hemangiossarcoma/radioterapia , Hemangiossarcoma/diagnóstico , Lipossarcoma Mixoide/genética , Lipossarcoma Mixoide/radioterapia , Células Endoteliais/patologia , Vasos Linfáticos/patologia , Neoplasias Cutâneas/patologia
16.
Clin Nucl Med ; 47(12): 1114-1115, 2022 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-36342800

RESUMO

ABSTRACT: Epithelioid angiosarcoma in the aortic arch with metastatic disease is extremely rare. We report a case of 63-year-old man with suspected bone metastases who underwent 18F-FDG PET/CT for seeking the potential primary tumor. PET/CT demonstrated intense FDG uptake in the aortic arch with multiple FDG-avid lesions involving the lung, lymph nodes, and bones. Finally, the diagnosis of primary aortic epithelioid angiosarcomas with metastatic disease was confirmed.


Assuntos
Hemangioendotelioma Epitelioide , Hemangiossarcoma , Segunda Neoplasia Primária , Masculino , Humanos , Pessoa de Meia-Idade , Fluordesoxiglucose F18 , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Hemangiossarcoma/diagnóstico por imagem , Hemangiossarcoma/patologia , Tomografia por Emissão de Pósitrons
19.
Am J Vet Res ; 83(12)2022 Nov 07.
Artigo em Inglês | MEDLINE | ID: mdl-36327166

RESUMO

OBJECTIVE: To determine luteinizing hormone receptor (LHR) expression and response to LHR activation in isolated canine splenic hemangiosarcoma cell lines in vitro. SAMPLES: In vitro cultures of commercially available canine splenic hemangiosarcoma cell lines (EFS, GRACE-HSA, and DAL-4). PROCEDURES: The percentage of each cell line expressing LHR was determined by immunocytochemistry. Cells were then treated with increasing doses (7.5 ng/mL, 75 ng/mL) of recombinant canine luteinizing hormone (cLH) for 48 hours and evaluated using a cell proliferation assay. RESULTS: The percentage of cells expressing LHR was 17.2 ± 4.5%, 11.8 ± 3.1%, and 6.9 ± 2.5% in EFS, GRACE-HSA, and DAL-4, respectively. There was significant increase in cell count in the DAL-4 and EFS cell lines following a 48-hour incubation at the highest cLH concentration (P = .028 and P = .019, respectively). There was not a significant increase in cell count in the GRACE-HSA cell line at either cLH concentration. CLINICAL RELEVANCE: Activation of LHR results in cell proliferation in some canine splenic hemangiosarcoma cell lines. These results may explain why spayed and castrated dogs with high circulating LH concentrations may develop hemangiosarcoma more frequently than intact dogs.


Assuntos
Doenças do Cão , Hemangiossarcoma , Neoplasias Esplênicas , Cães , Animais , Hemangiossarcoma/veterinária , Hemangiossarcoma/tratamento farmacológico , Receptores do LH/genética , Doenças do Cão/tratamento farmacológico , Neoplasias Esplênicas/veterinária , Linhagem Celular Tumoral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...